Please assess the completion status of the following clinical trial:

Trial Title: Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 25 to 65 years of age, inclusive, at the Screening Visit.~* AHI 10 to 50 (hypopneas defined by 4% oxygen desaturation)~* History of hypertension or blood pressure at Visit 1 ≥130/80 mmHg~Exclusion Criteria:~* History of narcolepsy.~* Clinically significant craniofacial malformation.~* Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control. A medication for these purposes is defined by dosage form, such that a combination antihypertensive medication is considered 1 medication~* CPAP should not be used for at least 2 weeks prior to first study PSG~* History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used during participation in the study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AD113 (Type: EXPERIMENTAL): Two oral capsules administered before bed
- Atomoxetine (Type: EXPERIMENTAL): Two oral capsules administered before bed

Based on this trial design, predict the completion outcome and termination type (if applicable).